Biotechnology company Massive Bio has introduced a new free portal called Patient Connect to enable cancer patients to navigate their clinical trial journey from anywhere.
The platform will allow the patients to find the appropriate clinical trial for them in the language of their choice after they provide consented access to their medical records.
Patient Connect, leveraging Massive Bio’s AI-powered multi-trial matching system, will allow the patients to identify the best clinical trial options based on their personal diagnosis, biomarkers, treatment history and geographic location.
Additionally, the patients can download their clinical trial matching reports and share them with their physicians and family members.
Further, Massive Bio provides concierge services where the company’s patient relations coordinators answer patient’s queries, offer guidance, and assist with the enrolment process.
The offering is expected to increase treatment access possibilities irrespective of geographical constraints.
Massive Bio chief medical officer and co-founder Dr Arturo Loaiza-Bonilla said: “Patient Connect redefines how patients engage with clinical trials, offering them a lifeline to new treatment possibilities and hope for better outcomes.”
According to Massive Bio, the company has successfully matched patients to more than 33,000 clinical trial sites. The US-based firm has also claimed in a recent publication that their unique multi-trial matching approach, in collaboration with the Precision Cancer Consortium, resulted in up to 12-fold increase in patient eligibility for a clinical trial.
Massive Bio chief product officer Oz Hüner said: “Patient Connect empowers people to intuitively navigate the clinical trial enrolment process, keeping patients connected to their physicians and loved ones throughout their personal journey.”
